Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Gains from Investment Securities (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Gains from Investment Securities readings, the most recent being $5.4 million for Q3 2025.

  • Quarterly Gains from Investment Securities rose 92.07% to $5.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$1.1 million through Dec 2025, up 8.96% year-over-year, with the annual reading at $7.2 million for FY2025, 31.97% down from the prior year.
  • Gains from Investment Securities hit $5.4 million in Q3 2025 for Terns Pharmaceuticals, up from $244595.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $11.4 million in Q2 2024 and bottomed at -$1.2 million in Q4 2024.
  • Average Gains from Investment Securities over 5 years is $2.3 million, with a median of $1.1 million recorded in 2022.
  • The largest annual shift saw Gains from Investment Securities skyrocketed 3944.01% in 2024 before it crashed 97.85% in 2025.
  • Terns Pharmaceuticals' Gains from Investment Securities stood at $142429.0 in 2021, then crashed by 104.21% to -$6000.0 in 2022, then surged by 138364.48% to $8.3 million in 2023, then crashed by 114.73% to -$1.2 million in 2024, then soared by 542.75% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Gains from Investment Securities are $5.4 million (Q3 2025), $244595.0 (Q2 2025), and $104000.0 (Q1 2025).